NCCT Stroke, created by RapidAI, receives FDA clearance
Creator of AI-enhanced clinical decision support and patient workflow platform, RapidAI, announces it has received FDA 510(k) clearance for Rapid NCCT Stroke.
According to the company, Rapid NCCT Stroke uses artificial intelligence to analyze non-contrast CT (NCCT) images to determine suspicion of ICH and LVO of the distal internal carotid artery (ICA) and middle cerebral artery (MCA-M1). The fully automated system then delivers triage and prioritization notifications through PACS, email, and the Rapid mobile app.
Company leaders state that Rapid NCCT Stroke supports teams in: accelerating door-to-imaging and door-to-decision time; making faster transfer decisions; improving equity of care by giving centers of all levels greater access to advanced value-based CT imaging technology that may improve decision making and impact patient outcomes
“This technology will not only have an enormous impact on stroke care here in the U.S. but also globally by giving care teams at small, local, or regional facilities around the world access to advanced clinical decision support technology too often only available at comprehensive stroke centers,” commented Karim Karti, CEO of RapidAI. “Our hope is that by providing better information early for more informed treatment and transfer decisions, Rapid NCCT Stroke will support faster stroke care and better patient outcomes.”
For more information about RapidAI visit: https://www.rapidai.com/stroke
